Liao Yujing,Huang Jing,Hu Xiaoyun,et al.. A retrospective analysis of clinical diagnosis and multi-disciplinary team treatment in patients with primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 512-516.
[1] Gish RG,Lencioni R,Di Bisceglie AM,et al. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol,2012,6(2):173-185. [2] 陈建国,陆建华,朱源荣,等. 乙型肝炎病毒感染与肝癌发生的31年随访研究. 中华流行病学杂志,2010,31(7):721-726. [3] 陈建国,陈万青,张思维,等. 中国2003-2007年肝癌发病率与死亡率分析. 中华流行病学杂志,2012,33(6):547-553. [4] Ryder SD,British Society of Gastroenterology.Guidelines for the diagnosis and treatment of hepatocellular carcinoma in adults. Gut,2003,52:iii1-8. [5] Kurpad R,Kim W,Rathmell WK,et al. A multidisciplinary approach to the management of urologic malignancies:does it influence diagnostic and treatment decisions. Urol Oncol,2011,29(4):378-382. [6] 王悦华,王珍. 医学家整体治疗策略在肿瘤治疗设计中的作用.综述与进展,2011,40(7):140-144. [7] Chang TT,Liaw YF,Wu SS,et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology,2010,52:886-893. [8] Quiroz SC,Bucio L,Souza V,et al. Effect of endotoxin pretreatment on hepatic stellate cell response to ethanol and acetaldehyde. J Gastroenterol Hepatol,2001,16(11):1267-1273. [9] Evans AA,Chen G,Ross EA,et al. Eight-year follow-up of the 90,000-person HaiMen city cohort:I. Hepatocellular carcinoma mortality,risk factors,and gender differences. Canc Epidemiol Biomark Prev,2002,11:369-376. [10] Alka S,Hemlata D,Vaishali C,et al.Hepatitis B viru surface(S) transactivator with DNA-binding properties. J Med Virol,2000,61:1-10. [11] Murakami Y,Saigo K,Takashima H,et al. Large scaled analysis of HBV DNA integration in HBV related hepatocellular carcinomas. Gut,2005,54:1162-1168. [12] Yang HI,Lu SN,Liaw YF,et al.Hepatitis B e antigen and the risk of the hepatocellular carcinoma.N Engl J Med,2002,347:168-174. [13] Fattovich G,Stroffolini T,Zagin I,et al. Hepatocellular carcinoma in cirrhosis:incidence and risk factors. Gastroenterology,2004,127:S35-50. [14] Cucchetti A,Trevisani F,Cescon M,et al. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. J Hepatol,2012,56(5):1089-1096. [15] Chen CJ,Yang HI,Su J,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA,2006,295:65-73. [16] Van Roey G,Fevery J,Van Steenbergen W,et al. Hepatocellular carcinoma in Belgiu: clinical and virological characteristics of 154 consecutive cirrhotic and non-cirrhotic patients. Eur J Gastroenterol Hepatol,2000,12:61-66. [17] Wong GL,Chan HL,Mak CW,et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology,2013,58(5):1537-1547. [18] Mok TS,Yu SC,Lee C,et al.Fasle-negative rate of abdominal sonography for detecting hepatocellular carcinoma in patients with hepatitis B and elevated serum fetoprotein levels.Am J Roentgenol,2004,183:453-458. [19] ShirakawaH,Kumnuma T,Nishmiura Y,et al. Glypiean-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.Int J Oncol,2009,34(3):649-656. [20] Baek YH,Lee JH,Jang JS,et al. Diagnostic role and correlation with staging system s of PIVKA-II compared with AFP.Hepatogastroenterology,2009,56(91-92):763-767. [21] Lok AS,Sterling RK,Everhart JE,et al. Des-gamma-carboxy prothromb in and alpha fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology,2010,138(2):493-502. [22] Lencioni R.Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. Oncology,2010,78(suppl 1):107-112. [23] 骆抗先,陈金军,李平,等. 乙型肝炎基础和临床. 北京:人民卫生出版社,2007:647-650. [24] Kim MY,Oskarsson T,Acharyya S,et al. Tumor self-seeding by circulating cancer cells. Cell,2009,139:1315-1326. [25] Ferenci P,Fried M,Labrecque D,et al. World Gastroenterology Organisation Guideline. Hepatocellular carcinoma(HCC):a global perspective. J Gastrointestin Liver Dis,2010,19(3):311-317. [26] Barone C,Koeberle D,Metselaar H,et al. Multidisciplinary approach for HCC patients:hepatology for the oncologists.Ann Oncol,2013,24( suppl 2):ii15-23. [27] Patkar V,Acosta D,Davidson T,et al. Cancer multidisciplinary team meetings:evidence,challenges,and the role of clinical decision support technology. Int J Breast Cancer,2011:831605. [28] Chang TT,Sawhney R,Monto A,et al. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival.HPB(Oxford),2008,10(6):405-411. [29] 中国抗癌协会肝癌专业委员会,等. 原发性肝癌规范化诊治的专家共识. 实用肝脏病杂志,2009,12(5):259-269. [30] 广东省抗癌协会肝癌专业委员会,等. 肝癌多学科联合治疗策略与方法—广东专家共识(2). 中国实用外科杂志,2014,8(34):735-738.